304 related articles for article (PubMed ID: 17616393)
1. Aromatase and COX in breast cancer: enzyme inhibitors and beyond.
Brueggemeier RW; Su B; Sugimoto Y; Díaz-Cruz ES; Davis DD
J Steroid Biochem Mol Biol; 2007; 106(1-5):16-23. PubMed ID: 17616393
[TBL] [Abstract][Full Text] [Related]
2. Selective regulation of aromatase expression for drug discovery.
Brueggemeier RW; Su B; Darby MV; Sugimoto Y
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):207-10. PubMed ID: 19931613
[TBL] [Abstract][Full Text] [Related]
3. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
Brueggemeier RW; Díaz-Cruz ES; Li PK; Sugimoto Y; Lin YC; Shapiro CL
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):129-36. PubMed ID: 15964185
[TBL] [Abstract][Full Text] [Related]
4. Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.
Su B; Diaz-Cruz ES; Landini S; Brueggemeier RW
J Med Chem; 2006 Feb; 49(4):1413-9. PubMed ID: 16480277
[TBL] [Abstract][Full Text] [Related]
5. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.
Brueggemeier RW; Díaz-Cruz ES
Minerva Endocrinol; 2006 Mar; 31(1):13-26. PubMed ID: 16498361
[TBL] [Abstract][Full Text] [Related]
6. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.
Díaz-Cruz ES; Brueggemeier RW
Anticancer Agents Med Chem; 2006 May; 6(3):221-32. PubMed ID: 16712450
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
Díaz-Cruz ES; Shapiro CL; Brueggemeier RW
J Clin Endocrinol Metab; 2005 May; 90(5):2563-70. PubMed ID: 15687328
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
Su B; Landini S; Davis DD; Brueggemeier RW
J Med Chem; 2007 Apr; 50(7):1635-44. PubMed ID: 17315855
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer.
Salhab M; Singh-Ranger G; Mokbel R; Jouhra F; Jiang WG; Mokbel K
J Surg Oncol; 2007 Oct; 96(5):424-8. PubMed ID: 17657731
[TBL] [Abstract][Full Text] [Related]
11. The role of cyclooxygenase-2-dependent signaling via cyclic AMP response element activation on aromatase up-regulation by o,p'-DDT in human breast cancer cells.
Han EH; Kim HG; Hwang YP; Choi JH; Im JH; Park B; Yang JH; Jeong TC; Jeong HG
Toxicol Lett; 2010 Oct; 198(3):331-41. PubMed ID: 20678559
[TBL] [Abstract][Full Text] [Related]
12. Aromatase and cyclooxygenases: enzymes in breast cancer.
Brueggemeier RW; Richards JA; Petrel TA
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):501-7. PubMed ID: 14623550
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Richards JA; Petrel TA; Brueggemeier RW
J Steroid Biochem Mol Biol; 2002 Feb; 80(2):203-12. PubMed ID: 11897504
[TBL] [Abstract][Full Text] [Related]
14. Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification.
Su B; Tian R; Darby MV; Brueggemeier RW
J Med Chem; 2008 Mar; 51(5):1126-35. PubMed ID: 18271519
[TBL] [Abstract][Full Text] [Related]
15. 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.
Su B; Mershon SM; Stonerock LA; Curley RW; Brueggemeier RW
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):40-6. PubMed ID: 18248980
[TBL] [Abstract][Full Text] [Related]
16. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators.
Gueto C; Torres J; Vivas-Reyes R
Eur J Med Chem; 2009 Sep; 44(9):3445-51. PubMed ID: 19278756
[TBL] [Abstract][Full Text] [Related]
17. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression.
Wang Y; Man Gho W; Chan FL; Chen S; Leung LK
Br J Nutr; 2008 Feb; 99(2):303-10. PubMed ID: 17761019
[TBL] [Abstract][Full Text] [Related]
18. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
Agarwal VR; Bulun SE; Leitch M; Rohrich R; Simpson ER
J Clin Endocrinol Metab; 1996 Nov; 81(11):3843-9. PubMed ID: 8923826
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancer.
Irahara N; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2006 Nov; 243(1):23-31. PubMed ID: 16556483
[TBL] [Abstract][Full Text] [Related]
20. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer.
Salhab M; Reed MJ; Al Sarakbi W; Jiang WG; Mokbel K
Breast Cancer Res Treat; 2006 Sep; 99(2):155-62. PubMed ID: 16541304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
